Monday 10 November 2014

Competitor Analysis: Cardiovascular Peptides, New Report Launched

Competitor Analysis: Cardiovascular Peptides

The present Competitive Intelligence Report about Cardiovascular Peptides used to treat or prevcent heart failure, myocardial infarction, thrombosis, hypertension, peripheral vascular diseases, hemostasis and wound sealing provides a competitor evaluation in the field of R&D projects with cardiovascular peptides as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of current active projects in research and development of cardiovasuclar peptides. In addition, the report lists company-specific R&D pipelines of cardiovascular peptides.

Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Competitor Analysis Series
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 59 pages “Competitor Analysis: Cardiovascular Peptides” report covering 2013 Sales of Major Cardiovascular Peptides, Acute Care & Reperfusion Injuries, Heart Failure, Coronary Ischemia & Myocardial Infarction, Cardiometabolic Disease & Atherosclerosis, Peripheral Vascular Disease Hypertension, Pulmonary Artery Hypertension, Hemostasis, Wound Sealing & Prevention of Thrombosis, Hematologic Diseases, Corporate Cardiovascular Peptide R&D Pipelines.

Know more about this report athttp://mrr.cm/ZjV

No comments:

Post a Comment

Note: only a member of this blog may post a comment.